After years of failed attempts, a bipartisan coalition in Congress believes it finally has the votes to pass meaningful prescription drug pricing reform — legislation that pharmaceutical companies are spending hundreds of millions of dollars to defeat.
The Proposal
The bill would allow Medicare to negotiate directly with drug manufacturers for the first time, capping out-of-pocket costs for seniors at $2,000 annually and establishing an inflation penalty that would require companies to rebate Medicare if prices rise faster than inflation.
The Lobbying Campaign
PhRMA, the industry’s main trade association, has deployed over 1,400 registered lobbyists and committed $150 million to an advertising campaign targeting swing-district members of Congress. The campaign argues that price controls will reduce investment in new drug development.
Counterarguments
Independent economic analyses dispute the industry’s projections, noting that the United States already pays two to four times what peer nations pay for identical medications. A study published last month found no correlation between domestic drug pricing and global R&D investment levels.
Timeline
Leadership has indicated a floor vote could come within three weeks. The White House has publicly committed to signing the bill if it passes in its current form, a significant shift from earlier administrations that avoided direct confrontation with the pharmaceutical industry.
